Daily Stock Market Report (Mon 17 Feb 2025) - Agenda
Good morning! We've finished the Agenda now.
Name (Mkt Cap)RNSSummaryOur view (Author)Assura (LON:AGR) (£1.3bn)Possible OfferKKR says it made four proposals to buy AGR, latest at 48p. All were rejected by AGR board (SP: 39p).MONY (LON:MONY) (£1.0bn)Final Results2024 rev +2% to £439m, adj EPS +5% to 17.1p. 2025 adj EBITDA to be “broadly within” consensus.Oxford BioMedica (LON:OXB) (£414m)Full Year TU2024 was in line. Organic revenue growth 78-81%. EBITDA profitability in H2. Outlook in line.Frp Advisory (LON:FRP) (£344m)TU amp; DividendFY April 2025 will be ahead of expectations. All service pillars ahead. Q3 divi 0.95p (LY: 0.9p).Wilmington (LON:WIL) (£336m)Half-year ReportTrading is in line. Net cash £31m. Organic revenue +3%, total revenue +16% (acquisitions).hVIVO (LON:HVO)£2m contract winNew client has signed contract for a hMPV trial following hVIVO/s successful recent hMPV pilot.Springfield Properties (LON:SPR) (£117m)Interim Results amp; Land Sale Agreement£64m land sale to Barratt. H1 adj PBT up 90% to £3.8m. FY25 profit to be sig. ahead of exps.Creo Medical (LON:CREO) (£78m)FY24 TU